Home > Resources > Whitepapers > How to Win Biotech Funding

How to Win Biotech Funding

September 27, 2019

The report provides an in-depth look at successful, proven approaches to investor presentations used today by hundreds of biotech and other life sciences executives.

Spotlight

Center for Human Genetics

The Center for Human Genetics (Centrum Menselijke Erfelijkheid) is active in three domains: research, teaching and health services. The center focuses on hereditary diseases, cancer and neurological disorders. Its collaborators want to gain a better insight into these diseases, in order to assure patients a correct and timely diagnosis and a better treatment and support.

OTHER WHITEPAPERS

Innovative strategies to maintain product integrity in Biologic andBiosimilar clinical studies

whitePaper | August 7, 2022

The number of biologic new molecular entities approved by the FDA has increased over the last five years indicates a growing focus on biosimilar.

Improve Your Gene-Editing Success With CRISPR-SNIPER Technology

whitePaper | February 15, 2023

The discovery of both CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and associated proteins, the Cas nucleases, has revolutionized the field of gene-editing.

Risk assessment of fungal materials

whitePaper | February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

Recruitment, Retention & Diversity: The Evolution of Patient Engagement in Clinical Trials

whitePaper | January 23, 2023

Recruitment, retention, and diversity are critical elements of clinical trials that, if insufficient, can jeopardize successful trial completion.

How Can Biotechnology and Pharmaceutical Industries Better Weather This New Economy?

whitePaper | October 10, 2022

Biotechnology and pharmaceutical industries continue to experience increased pressure on financial performance due to several factors.

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.